Abstract: Diabetic retinopathy and diabetic macular edema comprise a major source of visual disability throughout the developed world. The etiology and pathogenesis of macular edema is intricate and multifactorial, in which the hyperglycemic state in diabetes induces a microangiopathy. Through several inflammatory and vasogenic mediators, including vascular endothelial growth factor (VEGF) upregulation and inflammatory cytokines and chemokines, pathologic changes are induced in the vascular endothelium triggering breakdown of the blood retinal barrier, causing extravasation of fluid into the extracellular space and manifesting clinically as macular edema, resulting in visual loss. The advent of medications targeting the VEGF pathway has led to great clinical improvements compared with the previous standard of care of laser therapy alone, as shown in studies such as RISE, RIDE, VIVID, VISTA, and DRCR. However, analyses have shown that many patients have inadequate response or are nonresponders to anti-VEGF therapy, demonstrating the need for additional therapies to more comprehensively treat this disease. Although corticosteroid treatments and implants have demonstrated some efficacy in adjunctive and supplemental treatment, the need to more adequately treat macular edema remains. Our knowledge of diabetic macular edema continues to grow, leading to new currently available and emerging pharmacotherapies to further enhance our treatment and restore vision in those affected by diabetic macular edema. This review will discuss the pathogenesis of diabetic macular edema and the pharmacologic therapies available for its treatment, including anti-VEGF, steroids, and newer therapies still in development, such as angiopoietin antagonists, Tie2 agonists, kallikrein inhibitors, interleukin inhibitors, and others.
D
iabetic macular edema is a major public health concern, representing the major cause of visual loss in individuals with diabetic retinopathy. Diabetes mellitus is a global pandemic disease that has continued to rise in prevalence as rates of obesity, sedentary lifestyle, and urbanization increase. Diabetic retinopathy is often one of the first clinical manifestations of the disease and is the major cause of blindness in working age individuals in industrialized nations. 1 The pathogenesis of diabetic macular edema is multifactorial and complex, with the hyperglycemic state caused by diabetes inducing multiple pathologic abnormalities, ultimately producing the sight-threatening conditions of macular edema and proliferative, neovascular retinopathy.
Although historically diabetic macular edema has been treated with laser photocoagulation and pars plana vitrectomy, recent advances in pharmacological therapies demonstrated remarkable effectiveness in the treatment of macular edema. Specifically, anti-vascular endothelial growth factor (VEGF) therapy has proved to have significant clinical benefits in improving macular edema anatomically along with providing impressive visual acuity gains in individuals suffering from the disease. Although anti-VEGF therapy has provided a new standard of care in macular edema, the existence of many individuals that have persistent, chronic macular edema that is refractory to anti-VEGF therapy alone represents the fact that this approach is often an incomplete treatment. Other current and emerging treatments target other molecules in the biochemical pathway of macular edema and represent the promise of a more comprehensive therapy. This review will provide an overview of the pathophysiology of diabetic macular edema, along with an evaluation and discussion of current and emerging therapies for the disease. Although laser and surgical therapy represent important historical context that still provide an invaluable component of the overall treatment for these patients, this article will focus on the current and developing pharmacotherapies for macular edema (Table 1) .
PATHOPHYSIOLOGY
Hyperglycemia is considered the primary metabolic abnormality in diabetes mellitus that results in the pathologic changes of diabetic retinopathy and diabetic macular edema. The relationship between control of hyperglycemia and onset and severity of diabetic retinopathy has been well established, with 2 landmark epidemiologic studies, the Diabetes Control and Complications Trial and the United Kingdom Prospective Diabetic Study, showing that stricter control of glycemia results in lower risk of development and progression of retinopathy in both type 1 and type 2 diabetics, respectively.
2,3
The chronic hyperglycemic state in uncontrolled diabetes results in a microangiopathy and degenerative neuoretinopathy. Hyperglycemia activates deleterious intracellular metabolic pathways, including the hexosamine and polyol pathways, activation of protein kinase C, and results in increased glycosylation of proteins forming advanced glycosylation end products and formation of free radicals. 4 The activation of these pathways induces intracellular derangements, causing proteolytic enzymatic degradation and mitochondrial dysfunction. Accumulation of glycosylated end products results in changes in the extracellular matrix, along with increasing oxidative stress via formation of reactive oxygen species and expression of inflammatory markers and initiation of the inflammatory cascade. The changes to extracellular matrix result in a stiffer, less compliant vascular network, and the increased oxidative stress causes death of the vascular pericytes.
5
Vascular endothelial cells are similarly lost, and the integrity and function of the proteins of the tight junctions are compromised and altered.
6,7
The blood-retinal barrier maintains fluid homeostasis by regulating the passage of fluid and proteins from the vascular space into the retina. It comprises the inner blood-retina barrier, consisting of the retinal vessels, and the outer blood-retinal barrier, consisting of the chorioretinal interface regulated by the retinal pigment epithelium. Both the inner and outer blood-retinal barriers are maintained by the tight junctions between the cells that comprise them. Cumulatively, the cellular derangements mentioned above, namely, tight junction breakdown and loss of pericytes and endothelial cells, result in hyperpermeability of the retinal capillary network and breakdown of the inner blood-retinal barrier, causing extravasation of fluid, electrolytes, and sometimes larger macromolecules into the extracellular space.
8 This manifests clinically as diabetic macular edema.
An additional effect of the initial biochemical abnormalities caused by hyperglycemia is retinal hypoxia that is induced via capillary obstruction. As inflammatory markers, such as inflammatory intercellular adhesion molecule-1 (ICAM-1), are produced and expressed on the endothelial surface, leukocyte adhesion occurs between the leukocytes and the endothelial cells, resulting in capillary obstruction.
9 These inflammatory markers are produced as part of the hyperglycemia-induced exposure to advanced glycosylation end products. With the increased retinal hypoxia that is created by this capillary obstruction, there is increased expression of VEGF, which has been shown to be one of the most important factors in the pathogenesis of diabetic retinopathy and macular edema. Vascular endothelial growth factor is elevated up to 10 times higher in the vitreous compared with nondiabetic patients, and VEGF expression further increases vascular permeability and breakdown of the blood-retinal barrier, causing worsening macular edema. 5 Vascular endothelial growth factor has emerged as an important therapeutic target in the treatment of diabetic macular edema, and anti-VEGF agents have found great success, becoming the gold standard, first-line treatment in individuals with diabetic macular edema.
Additionally, neurodegeneration is an early event that precedes the vascular abnormalities seen in diabetic retinopathy but contributes to the complex pathogenesis of macular edema. This neurodegeneration occurs by neuronal apoptosis and glial proliferation, which is induced via injury from free radicals, advanced glycosylation end products, and inflammatory mediators. Subsequently, there is an accumulation of the neurotransmitter glutamate and NMDA receptors, which mediate breakdown of the blood-retinal barrier by upregulation of VEGF expression and loss of neuroprotective factors.
10
Diabetic macular edema results in retinal thickening and disruption of the normal retinal architecture. Early in the course of the disease, this retinal thickening reduces visual function by exerting a physical effect on the path of light through the retina to the photoreceptors. Retinal thickening causes changes in the retinal transparency and refractive index. In chronic macular edema, neural retinal damage and glial reactions cause disruption and degradation of the photoreceptor layer. Macular ischemia and disorganization of retinal inner layers persist even after resolution of the macular edema and further impede normal retinal function and exacerbate vision loss in chronic macular edema. 7 Although VEGF has been found to be an integral molecule to the development of macular edema, the disease is multifactorial and there are numerous potential therapeutic targets involved in the pathogenesis. As mentioned above, inflammatory mediators and the inflammatory cascade are heavily involved in the pathogenesis of diabetic retinopathy and macular edema, particularly in the chronic stages of the disease.
11,12 The increased oxidative stress, reactive oxygen species, and advanced glycosylated end products in diabetes induce expression of inflammatory cytokines (such as IL-6, IL-8, IL-1β, and TNF-α), chemokines (CCL2, CCL5, CXCL8, CXCL10, and CXCL12), and adhesion molecules (ICAM-1, VCAM-1), which in turn activate and direct migration of leukocytes, resulting in leukostasis. 13, 14 In addition to the capillary closure and subsequent retinal hypoxia mentioned above, these inflammatory mediators also induce endothelial cell death directly via apoptotic biochemical pathways and by leukocyte-induced endothelial cell death that occurs during leukostasis. These pathways culminate in the degeneration of the retinal capillary bed causing blood-retinal barrier breakdown and macular edema. In chronic, refractory macular edema, the inflammatory molecules comprise an even more significant role. 6 As reactive oxygen species and other sources of oxidative stress accumulate, a self-perpetuating cycle occurs as the cytotoxic effects of these mediators cause production of additional reactive oxygen species.
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CURReNT TReATMeNTS
Anti-VeGF
As reviewed above, investigations into the pathophysiology of diabetic macular edema elucidated the pivotal role VEGF plays in the initiation and propagation of edema and exudation. Consequently, multiple clinical trials were conducted, and intravitreal medications targeting VEGF were found to provide significant benefits in the treatment of macular edema and have since become the standard of care for the treatment of center-involving diabetic macular edema not amenable to focal photocoagulation treatment.
Ranibizumab (Lucentis, Genentech, San Francisco, CA) was the first medication approved by the United States Food and Drug Administration (FDA) for the treatment of diabetic macular edema and one of the first anti-VEGF therapies extensively studied and its effectiveness validated in major phase 3 clinical trials. 16, 17 Ranibizumab consists of a humanized monoclonal antibody fragment that binds to all isoforms of VEGF-A. RISE and RIDE were 2 major phase 3, randomized controlled trials that compared monthly ranibizumab with sham injections. The percentage of patients with a greater than 15 letter gain in visual acuity from baseline at both 2-and 3-year end points was approximately double in patients receiving ranibizumab compared with those receiving sham, roughly 40% compared with 20%. 18, 19 The Diabetic Retinopathy Clinical Research Network (DRCR.net) protocol I was another phase 3 trial with 4 treatment arms, comparing sham injection with laser photocoagulation, with intravitreal ranibizumab with either prompt or deferred focal laser, and with intravitreal triamcinolone with prompt laser photocoagulation. This study yielded similar improvements seen in RISE and RIDE in visual acuity gains in patients treated with ranibizumab versus sham injection and when compared with intravitreal triamcinolone. Additionally, at long-term 5-year follow-up for these patients, it was found that the initial visual acuity gains at 1 year of treatment were maintained over 5 years, with a progressively decreasing frequency of treatment needed. 20 Ranibizumab has been found to be very effective biochemically and clinically, with aqueous levels of VEGF being completely suppressed after intravitreal injections and maintaining this suppression for an average of 33.7 days. 21, 22 Bevacizumab (Avastin, Genentech, San Francisco, CA), is a full-length humanized monoclonal antibody to VEGF, as opposed to the antibody fragment that compromises ranibizumab. Bevacizumab, initially developed as a chemotherapy, is not FDA approved for treatment of diabetic macular edema but has found significant, widespread off-label use for that indication. The BOLT study was another randomized control trial comparing treatment with intravitreal bevacizumab with laser therapy and showed that the bevacizumab arm had a mean gain of +8.6 letters at 2 years, compared with a mean loss of −0.5 letters in the laser arm. A total of 32% of patients also gained at least 15 letters from baseline compared with 4% in the laser photocoagulation group. 23 Other smaller studies have found similar benefits in treatment with bevacizumab compared with focal laser. 24, 25 Aflibercept (Eylea, Regeneron, New York, NY) is a soluble fusion protein, a VEGF receptor analog consisting of the extracellular domains of VEGF receptors fused with human immunoglobulin. The VIVID and VISTA studies were the major landmark studies that investigated the use of aflibercept in diabetic macular edema and consisted of 2 parallel, phase 3 randomized controlled trials. VISTA was a multicenter study with sites across the United States, whereas VIVID consisted of sites across Europe, Japan, and Australia. The arms of the study consisted of aflibercept given every 4 weeks, aflibercept given every 8 weeks after 5 initial monthly doses, or laser photocoagulation. Both studies found an improvement in gains of visual acuity in those treated with aflibercept versus laser control, with VISTA showing gains of +10.4 letters with monthly aflibercept compared with +1.4 letters in laser and VIVID with similar gains +10.3 letters versus +1.6 letters. Additionally, the percentage of patients with a greater than 15 letter gain from baseline was higher with treatment with aflibercept, with 42.9% of patients in VISTA and 41.2% in VIVID achieving this with monthly aflibercept, compared with 13.6% and 18.9% with laser photocoagulation alone. 26 Based on these impressive clinical benefits, the FDA approved aflibercept for treatment of diabetic macular edema.
With regards to comparison between different anti-VEGF agents and their comparable effects on diabetic macular edema, the most comprehensive data comes from the DRCR.net protocol T. This study evaluated visual outcomes in patients with macular edema treated with ranibizumab, bevacizumab, or aflibercept up to every 4 weeks, with additional focal laser if indicated at or after 6 months. For initial visual acuities of 20/40 or better, there was found to be no statistically significant difference among the agents, with each therapy providing an improvement of about +8 letters at 1 year. For presenting visual acuities of 20/50 or worse, after 1 year of treatment, aflibercept was found to have statistically significantly greater gains in visual acuity compared with ranibizumab and bevacizumab (+18.9, +14.2, and +11.8, respectively). There were no statistically significant differences between ranibizumab and bevacizumab.
27 After 2 years of follow-up, in eyes with initial acuity of 20/50 or worse, the superior visual acuity gains of aflibercept compared with ranibizumab were not maintained (mean improvement of +18.1 and +16.1, respectively), although both aflibercept and ranibizumab maintained greater outcomes than bevacizumab in this group.
28 Some have interpreted these results to suggest that aflibercept should be first-line treatment of diabetic macular edema when visual acuity has declined to 20/50 or worse, although this remains controversial. 29, 30 Although the studies listed above have conclusively demonstrated the benefit of anti-VEGF therapy in the treatment of diabetic macular edema, especially when compared with the prior standard of care of laser photocoagulation, there has been a recognition that many patients are incomplete or nonresponders to anti-VEGF therapy and are being underserved by the current paradigm of anti-VEGF injections alone. 31 In subanalysis of the DRCR.net protocol I data of patients that were treated with intravitreal ranibizumab, when categorized based on whether a 20% reduction in central subfoveal thickness was achieved, approximately 50% of the patients received either inconsistent, variable responses or were nonresponders. 32 The EARLY analysis, another subanalysis of the DRCR.net protocol I data, stratified patients instead by their visual acuity gains at 12 weeks or after the first 3 ranibizumab injections. In this study, 37.1% of eyes had a greater than 10 letter visual gain, 23.2% with a 5 to 9 letter gain, and 39.7% of eyes with a suboptimal response, with a less than 5 letter gain. Additionally, within each response category, there was a less than 5 letter change from the initial visual acuity response over the remaining 52 to 156 week course of the study, suggesting that initial visual acuity response after 3 injections was predictive of long-term response and that eyes with initial suboptimal response showed poorer long-term response and visual outcomes. 33 Although the reason for the variability in response to treatment is incompletely understood, it seems that genetics play some role, with an individual patient's VEGF and VEGF receptor polymorphisms upregulating and downregulating gene products and transcription factors modulating and regulating anti-VEGF response.
6
Corticosteroids Due to the prevalence of patients poorly responsive to anti-VEGF therapy alone, other potential targets in the pathophysiology of macular edema that are independent of VEGF have been investigated. As there is a significant inflammatory component in the etiology of macular edema, steroids have been extensively evaluated as treatment options. Many inflammatory cytokines have been found to be elevated in aqueous samples in patients with diabetic retinopathy and have also been noted to correlate with the severity of retinopathy. This is in contrast to aqueous VEGF expression, which did not correlate to the severity of the retinopathy. 34 Corticosteroids inhibit these inflammatory mediators while having some anti-VEGF activity, whereas anti-VEGF therapy inhibits only VEGF itself. Corticosteroids also inhibit leukostasis and stabilize and reconstitute the blood-retinal barrier. 16, 35 Intravitreal triamcinolone was evaluated in the DRCR.net protocol I study, which, as discussed above, compared intravitreal ranibizumab with focal laser but also contained an arm of patients treated with 4 mg triamcinolone with prompt laser treatment. The triamcinolone group did not perform better than the group with sham injections and laser and was found to have inferior outcomes when compared with ranibizumab, with elevated rates of elevated intraocular pressure and cataract formation. However, in a subgroup analysis in patients that were pseudophakic at baseline, the triamcinolone group performed better than the sham injection and laser group and had similar visual acuity gains as the ranibizumab groups. 36 With the findings that steroid therapy can provide improved visual acuity for macular edema in the correct patient population after assessment of the risk of complications and the need to provide alternative therapy for macular edema refractory to anti-VEGF therapy, other additional intravitreal corticosteroid treatments have been developed. The other 2 commercially available, FDA-approved intravitreal steroids have been developed as sustained release formulations of more potent steroids and include the dexamethasone implant (Ozurdex, Allergan Inc, Irvine, CA) and the fluocinolone implant (Iluvien, Alimera Science, Alpharetta, GA). These sustained release formulations, with lower concentrations of drug being delivered over long time periods, can help reduce the frequency of injections and aid in issues of compliance.
The dexamethasone implant consists of a sustained release, biodegradable implant composed of a drug-copolymer complex that gradually elutes the drug over several months. This implant was evaluated in the MEAD study, which was a randomized controlled trial comparing 2 strengths of dexamethasone implant with sham injections. 37 A greater than 15 letter improvement was seen in 22% of the 0.7 mg dexamethasone implant group compared with 12% in the sham group, a statistically significant increase. Pseudophakic patients generally had a sustained improvement in acuity over the course of the study, whereas phakic patients experienced an initial improvement, followed by a decline and then recovery consistent with cataract formation and subsequent removal. The rate of cataract formation was 68%. Increases in intraocular pressure were managed with observation or topical medication. The BEVORDEX study consisted of patients with diabetic macular edema treated with either bevacizumab given up to every 4 weeks or dexamethasone implant given up to every 16 weeks on an as needed basis. Improvement of 10 letters or more was seen in equal amount in both groups, about 40%, with more patients in the dexamethasone group losing vision due to cataract formation. The bevacizumab group also required more frequent injections, a mean of 8.6 injections compared with 2.7 in the dexamethasone group over a 12-month period.
38 Several smaller studies have evaluated dexamethasone implants specifically in the setting of refractory, persistent diabetic macular edema with either dexamethasone monotherapy or in combination with anti-VEGF agents and have demonstrated effectiveness.
39-41
The DRCR.net protocol U is a larger, randomized controlled trial that recently published its results comparing combination dexamethasone and ranibizumab therapy with ranibizumab monotherapy in cases of refractory diabetic macular edema. One hundred twenty-nine eyes with persistent diabetic macular edema after at least 3 anti-VEGF injections were studied over a 6-month period and randomized to receive either combination therapy with ranibizumab as often as every 4 weeks with dexamethasone as often as every 3 months or ranibizumab with sham injections at the same interval. Although there was a significant difference in the decrease in the central thickness on optical coherence tomography in the combination group compared with the monotherapy group (−110 µm compared with −62 µm), this was not accompanied by visual acuity gains, as the mean improvement in acuity was similar between the 2 groups (2.7 letters versus 3.0 letters).
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The fluocinolone implant consists of a polyimide tube delivery system, which is not biodegradable, as opposed to the biodegradable dexamethasone implant. Fluocinolone is designed to be delivered at submicrogram levels over an even longer, extended period of 36 months. The FAME study was the major, phase 3 clinical trial assessing the fluocinolone implant's efficacy in treatment of diabetic macular edema. 43 The study compared low dose (0.2 µg/day) and high dose (0.5 µg/day) fluocinolone implants with sham injections. The percentage of patients with a greater than 15 letter acuity gain was found to be statistically increased in patients receiving fluocinolone compared with sham: 28.7% in the low dose group, 27.8% in the high dose group, and 18.9% in the sham group at 36 months. In subgroup analysis, patients with chronic macular edema of more than 3 years' duration fared markedly better with the insert compared with sham injection, with a greater than 15 letter acuity gain in 34.0% versus 13.4%, respectively. The authors hypothesize that such chronic edema may exacerbate the inflammatory effect in diabetic retinas. Nearly all patients with cataract at baseline developed one over the course of the study: 81.7% in the low dose and 88.7% in the high dose group.
NeW THeRAPeUTIC TARGeTS
Although anti-VEGF agents and steroids comprise the current commercially available therapies for diabetic macular edema, there are several new pharmacological agents in development to improve the current treatment paradigm. These novel agents target the molecules or signaling agents within the pathway for diabetic macular edema or target VEGF in a different manner than the current humanized antibodies. These novel agents hold promise in reducing the treatment burden in patients with macular edema and may prove useful in those individuals with macular edema resistant to anti-VEGF therapy.
44

Anti-VeGF DARPin
One proposed class of agents that also targets VEGF is the designed ankyrin repeat proteins (DARPins), which are genetically engineering mimetic proteins based on naturally occurring proteins in the human genome. These proteins have a small molecular weight, high stability, and high affinity for their targets. Their small size, high affinity, and high potency may allow them to overcome some limitations from immunoglobulin, with increased intravitreal half-lives reducing the need for frequent injections. 45 Abicipar pegol (Molecular Partners, Zurich, Switzerland) is a DARPin antagonist to VEGF-A in development. When injected intravitreally, aqueous levels of VEGF were found to be suppressed up to 8 to 12 weeks in individuals with diabetic macular edema, with sustained reductions in retinal thickness. 46 The PALM study is a phase 2 clinical trial evaluating its use in diabetic macular edema, comparing abicipar with monthly ranibizumab. The study met its endpoints, with all 3 of the abicipar treatment arms demonstrating efficacy and improvements in visual acuity and retinal thickness comparable with monthly ranibizumab with fewer injections needed. 47 
Angiopoietin/Tie2 Pathway
The angiopoietin pathway is another potential target in the pathogenesis of macular edema. Angiopoietins are a family of growth factors that interact with tyrosine kinase receptors located primarily on endothelial cells. These tyrosine kinase receptors are also known as Tie2 receptors. When these Tie receptors are activated or phosphorylated, they promote vascular stability by increasing endothelial cell survival, adhesion, and junctional stability, stabilizing the blood retinal barrier. Angiopoietin-2 (Ang-2) is upregulated in the hyperglycemic state and acts as a negative regulator of Tie receptors, increasing vasculature leakage and increasing responsiveness to VEGF and inflammatory cytokines. 16, 48 One agent in development is AKP-9778 (Aerpio Therapeutics, Cincinnati, OH), which is an inhibitor of the enzyme VE-PTP that subsequently increases Tie2 phosphorylation even in the presence of high angiopoietin-2 levels. Clinical trials conducted with AKP-9778 show reduction in diabetic macular edema with combination therapy with AKP-9778 and ranibizumab compared with ranibizumab alone.
49,50 AKB-9778 also is delivered subcutaneously, rather than intravitreally, twice daily and provided a gradual improvement in vision and anatomic outcomes over 28 days rather than an instantaneous effect.
Other potential therapies under development targeting the pathway include the monoclonal antibody RO6867461 (Roche, Basel, Switzerland), which is a biphasic immunoglobulin with one arm binding VEGF and the other Ang-2. The BOULEVARD study currently underway is a phase 2 trial comparing RO6867461 with ranibizumab. However, investigations of the use of another monoclonal antibody to Ang-2, nesvacumab (Regeneron, New York, NY), which was being coadministered with aflibercept in the RUBY study, 45 have yielded disappointing results. The phase 2 trial did not provide sufficient evidence to warrant further investigation in a phase 3 study, and Regeneron is suspending further development.
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Kallikrein-Kinin System
The kallikrein-kinin system (KKS) has been found to facilitate vascular hyperpermeability, leukostasis, cytokine production, and retinal thickening in rodent models of diabetic retinopathy. Plasma kallikrein, a serum protease, is the primary proinflammatory mediator of the KKS. Its products include bradykinin, an important component of hereditary angioedema. Components of the KKS were found to be elevated in type 1 and type 2 diabetics, and vitreous levels of KKS components were similarly elevated in patients with advanced diabetic retinopathy. 52, 53 Intravitreal injection with kallikrein or bradykinin was shown to increase retinal vascular permeability. Owing to its distinctness from the VEGF pathway, the KKS has garnered interest as a potential therapeutic target. KVD001 (Kalvista Pharmaceutical, Cambridge, MA), an intravitreally administered plasma kallikrein inhibitor, has been studied in a phase 1 trial involving patients with diabetic macular edema with promising results, including improvements in visual acuity and decreased retinal thickness. Phase 2 trials are planned for the near future. 45 
Integrin
Integrins are cell surface transmembrane receptors involved with attachments and interactions between cells and between cells and the extracellular matrix. These proteins regulate growth factors and activate intracellular signaling pathways. In the retina, they are located on the endothelial cells of the microvasculature and regulate angiogenesis. ALG-1001 (Allegro Ophthalmics, San Juan Capistrano, CA) is an integrin antagonist designed to inhibit interaction between integrins and the extracellular matrix. Studies have shown it to decrease angiogenesis and leakage from new, abnormal blood vessels in rodent models. 54 In addition to these potential benefits in the setting of diabetic retinopathy, it also acts as an inhibitor to the integrins at the vitreoretinal interface and can induce vitreolysis, similar to ocriplasmin, the protease approved for treatment of vitreomacular adhesion. By inducing vitreolysis and a posterior vitreous detachment, VEGF levels are lowered and do not accumulate over the macula, in addition to removing the vitreous scaffold for neovascularization and subsequent tractional detachment. These promising multiple mechanisms of potential action for treatment of diabetic macular edema have been accompanied by encouraging clinical trials, with the DEL MAR phase 2 trial showing noninferiority compared with monthly bevacizumab in terms of visual acuity gains and retinal thickness reductions, with less frequent need for injections with ALG-1001.
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Vascular Adhesion Protein
Vascular adhesion protein-1 (VAP-1) is an adhesion molecule expressed and located on the surface of endothelial cells. The protein is heavily involved with leukocyte adhesion and migration and thus is involved in the inflammatory pathway that, as reviewed above, is implicated in the pathogenesis of diabetic macular edema. In its soluble form, VAP-1 may be released from endothelial cells in the hyperglycemic state or in response to inflammatory cytokines. Rodent models showed promise with this therapy as well, with decreased retinal permeability with administration of VAP-1 inhibitors.
55 ASP8232 (Astellas Pharma Europe BV, Netherlands) is an orally administered VAP-1 inhibitor currently in the phase 2 VIDI trial, comparing ASP8232 versus ranibizumab versus combination therapy with both agents. 48 
Other Targets
In addition to the novel therapeutics discussed above, there are several other potential targets that are being investigated as potential areas of treatment for macular edema. As part of the inflammatory pathogenesis, inflammatory cytokine and chemokine inhibitors are in development. These include the interleukin-6 antibodies EBI-031 (Eleven Biotherapeutics, Cambridge, MA) and tocilizumab, currently in use for rheumatoid arthritis and systemic juvenile idiopathic arthritis but proposed for use with diabetic macular edema as well. 45 The rho-kinase pathway is involved with leukocyte adhesion to vascular endothelial cells, and fasudil (Asahi Kasei Pharma Corporation, Tokyo, Japan), a rho-kinase inhibitor, has shown some synergy with bevacizumab in treating resistant diabetic macular edema. 16, 56 Finally, squalamine is a small molecule that binds phospholipid membranes that blocks many, but not all, downstream effects of the VEGF pathway. It has been delivered as 0.2% eye drops (OHR-102; Ohr Pharmaceutical, New York, NY) in clinical trials combined with ranibizumab for age-related macular degeneration with some improvement compared with ranibizumab alone. 48 However, recent press releases have reported results from the phase 3 MAKO study where cotreatment with topical squalamine did not have visual acuity gains compared with ranibizumab alone.
57
CONCLUSIONS
Although our understanding of the pathogenesis and biomolecular pathways involved in diabetic macular edema continue to increase, the disease remains a major public health concern with significant disease burden. Additionally, though anti-VEGF therapy has revolutionized the management of these patients and provided a new standard of care, studies have shown that there remains a significant portion of patients with resistant, unresponsive, and chronic macular edema that are underserved with serial anti-VEGF injections alone. The reasons underlying this remain complex, with many mediators and signaling pathways not affected by VEGF. Although currently commercially available corticosteroid therapy offers an additional piece of the puzzle that treats many of the inflammatory mediators involved, the promise of new, novel agents targeting other components of macular edema's pathogenesis may provide continued improvements in patient outcomes and quality of life. The expanding pharmacologic toolbox available in the retina subspecialty allows for exciting new horizons in patient care.
